BIIB Stock — Price, Charts & Analysis

Biogen Inc. (BIIB) has a trailing P/E of 38.45x and a forward P/E of 13.09x. This places BIIB in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

BIIB trades with 38.45x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether BIIB looks overvalued or undervalued.

BIIB's P/E of 38.45x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

BIIB's trailing EPS is $5.63 and forward EPS is $16.54. Reported earnings growth is -84.80%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Biogen Inc. generated for each share. BIIB's trailing EPS is $5.63, and investors usually prefer EPS that is positive and growing over time.

Biogen Inc. has a market cap of $31.99B, making BIIB a large-cap stock based on the current market value shown on Worldtickers.

BIIB's latest stock price on Worldtickers is $216.48. The latest move is -$5.08 or -2.29%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

BIIB's quote includes a latest price of $216.48. The market open is $217.98. Previous close is $221.56. The intraday range is $216.32 to $221.29.

BIIB is down in the latest quote, with a move of -$5.08 or -2.29%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

BIIB generated $10.03B in trailing revenue. Revenue growth is 3.40%, which helps show whether demand is expanding or slowing.

BIIB's revenue growth is 3.40%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, BIIB shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $834.60M.

Gross margin is 78.32%. Margins show how efficiently Biogen Inc. turns revenue into profit.

Biogen Inc. carries $8.36B and holds $1.28B in cash.

BIIB holds $1.28B on its balance sheet.

BIIB's book value per share is $127.61.

Institutions hold 99.50% of BIIB shares. Insiders hold 0.19% of shares. Ownership mix helps investors understand how much of Biogen Inc. is held by professional investors and company insiders.

BIIB has 147.75M shares outstanding. Float shares are 147.22M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for BIIB, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for BIIB is $16.54. Earnings growth is -84.80%. Revenue growth is 3.40%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

BIIB's trailing EPS is $5.63. Forward EPS is $16.54. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

BIIB is in the Healthcare sector. Its earnings multiple is 38.45x. Its latest displayed growth metric is 3.40%. Compare these figures with sector peers before deciding whether Biogen Inc. is stronger or weaker than average.

BIIB trades at $216.48. The stock trades at 38.45x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Biogen Inc.'s fundamentals.

BIIB risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.16, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

BIIB should be compared with companies in Drug Manufacturers - General. Its earnings multiple is 38.45x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Biogen Inc. (BIIB) operates in Healthcare, specifically Drug Manufacturers - General. Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI,

BIIB trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

BIIB stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Biogen Inc.'s official website listed on Worldtickers is www.biogenidec.com/INVESTORS.aspx?ID=5494. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Biogen Inc. employs about 7.5K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Biogen Inc. is headquartered in Cambridge, MA, United States. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

BIIB is in the Healthcare sector and the Drug Manufacturers - General industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

BIIB has traded between $131.52 and $222.15 over the past 52 weeks. At $216.48, it is 2.55% below the high and 64.60% above the low. The 52-week range helps gauge long-term price momentum.

BIIB is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $204.86 and its 200-day moving average is $187.67.

BIIB's RSI is 59.13. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

BIIB's latest RSI reading is 59.13, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for BIIB is near $196.92. Key resistance is near $222.15. Breaks above resistance or below support can change the short-term technical setup.

BIIB's nearest reported support level is $196.92. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

BIIB's nearest reported resistance level is $222.15. A breakout above resistance can improve momentum, especially when volume confirms the move.

BIIB trades about 1.18M shares daily on average. The latest displayed volume is 325.72K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

BIIB's MACD is 1.12, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

BIIB is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 59.13 (neutral). MACD is bullish. Nearest support is around $196.92. Resistance is around $222.15. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $207.96 (4.09% from price). MA50 is $204.86 (5.67% from price). MA200 is $187.67 (15.35% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. BIIB's MA20 is $207.96. MA50 is $204.86. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

BIIB's pivot is near $219.60. Support is near $196.92. Resistance is near $222.15. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for BIIB is near $204.71. These levels help define risk and possible follow-through zones after a breakout or breakdown.

BIIB's Bollinger range is roughly $198.19 to $217.74. Band width is near 9.40%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

BIIB's ATR-based typical daily range is about 2.97%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 325.72K shares. Average volume is about 1.18M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

BIIB's all-time high shown on Worldtickers is $480.18. Its all-time low is $0.35. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

BIIB has a beta of 0.16, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.